Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications

Cancer Treatment Reviews

Volumn 38, Issue 1, 2012, Pages 36-53

  Custodio, Ana ^a   Méndez, Míriam ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Advanced non small cell lung cancer; Angiogenesis inhibitors; Combining targeted therapies; Epidermal growth factor receptor inhibitors; Multitargeted tyrosine quinase inhibitors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; ERLOTINIB; GEMCITABINE; PACLITAXEL; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; DISEASE SEVERITY; HUMAN; LUNG NON SMALL CELL CANCER; MUTATION; NONHUMAN; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 80155143972     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.04.001     Document Type: Review

References (203)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96.
2. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
4. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009, 27:1227-1234.
6. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
7. Pirker R., Pereira R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
8. Karp D.D., Paz-Ares L.G., Novello S., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522.
9. Soria J.C., Shepherd F.A., Douillard J.Y., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009, 20:1674-1681.
10. Marinov M., Fischer B., Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 2007, 63:172-182.
11. Cipriani N.A., Abidoye O.O., Vokes E., Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009, 63:169-179.
12. Tortora G., Caputo R., Damiano V., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003, 9:1566-1572.
13. Tortora G., Caputo R., Damiano V., et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic and antiangiogenic activity. Clin Cancer Res 2003, 9:866-871.
14. Herbst R., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
15. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 Study. J Clin Oncol 2009, 28:49-55.
16. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 2008, 26:650-656.
17. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
18. Hayes D.N., Monti S., Parmigiani G., et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006, 24:5079-5090.
19. Chen H.Y., Yu S.L., Chen C.H., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20.
20. Hirsch F.R., Varella-García M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
21. Tabernero J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007, 5:203-220.
22. Rocha-Lima C.M., Soares H.P., Raez L.E., et al. EGFR targeting of solid tumors. Cancer Control 2007, 14:295-304.
23. Ciardello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endtothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003, 9:1546-1556.
24. De Luca A., Carotenuto A., Rachiglio A., et al. The role of the EGFR signaling in tumor microenviroment. J Cell Physiol 2008, 214:559-567.
25. Ellis L. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004, 18:1007-1021.
26. Bianco R., Garofalo S., Rosa R., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008, 98:923-930.
27. Aviel-Ronen S., Blackhall F.H., Shepherd F.A., et al. K-ras mutations in non-small-cell lung carcinoma: A review. Clin Lung Cancer 2006, 86:981-986.
28. Rubin B.P., Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 2006, 86:981-986.
29. Camp E.R., Summy J., Bauer T.W., et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005, 11:397-405.
30. Viloria-Petit A.M., Kerbel R.S. Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies. Int J Radiat Biol Phys 2004, 58:914-926.
31. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib, erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2005, 2:e73.
32. Tonra J.R., Deevi D.S., Corcoran E., et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197-2207.
33. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006, 5:649-659.
34. Sandler A., Herbst R. Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006, 12:4421s-4425s.
35. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial groeth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors. Eur J Cancer 2006, 42:3127-3139.
36. Johnson Herbst.R.S., DH Mininberg.E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
37. Herbst R.S., ÓNeill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007, 25:4743-4750.
38. Hainsworth J., Herbst H. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standar first-line chemotherapy (BETA). J Thorac Oncol 2008, 3:S302.
39. Miller V.A., ÓConnor P., Soh C., et al. A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer. J Clin Oncol 2009, 27:18s. (suppl. abstr LBA8002).
40. Kabbinavar F.F., Miller V.A., Jonhson B.E., et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for fist-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 18:15s. (suppl; abstr 7526).
41. Gandara D., Kim E.S., Herbst R.S., et al. S0536: Carboplatin, paclitaxel, cetuximab, bevacizumab followed by cetuximab, bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 2009, 27:15s. (suppl; abstr 8015).
42. Mack P.C., Holland W.S., Redman M., AS K.R., et al. mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342, S0536. J Clin Oncol 2009, 27:15s. (suppl; abstr 8022).
43. Naumov G.N., Nilsson M.B., Cascone T., et al. Combined vascular endotelial growth factor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009, 15:3484-3494.
44. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
45. Holden S.N., Eckhardt S.G., Basser R., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16:1391-1397.
46. Tamura T., Minami H., Yamada Y., et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006, 1:1002-1009.
47. Natale R.B., Bodkin D., Govindan R., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results form a two-part, double-blind, randomized phase II study. J Clin Oncol 2009, 27:2523-2529.
48. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:5407-5415.
49. Heymach J.V., Johnson B.E., Parger D., et al. A randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
50. De Boer R., Arrieta O., Gottfried M., et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double blind phase III trial (ZEAL). J Clin Oncol 2009, 27:15s. (Abstract 8010).
51. Lee J., Hirsch V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28:15s. (Abstract 7525).
52. Natale R.B., Thongprasert S., Greco F.A., et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009, 27:15s. (Abstract 8009).
53. Ahn M., Park K., Ahn J.S., et al. Randomized, double-blind, placebo-controlled phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer (NSCLC) following 1st-line platinum-doublet chemotherapy. Ann Oncol 2010, 21:8s. (Abstract 418P).
54. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
55. Toner G.C., Mitchell P.L., de Boer R., et al. PET imaging study of SU11248 in patients with advanced malignancies. J Clin Oncol 2003, 22:191s. (Abstract 767).
56. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009, 101:1543-1548.
57. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
58. Groen H.J.M., Socinski M., Grossi F., et al. Randomized phase II study of sunitinib (SU) plus erlotinib (E) vversus placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21:8S. (Abstract 417P).
59. Scagliotti G.V., Krzakowski M., Szczesna A., et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study. Ann Oncol 2010, 21:8S. (Abstract LBA6).
60. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
61. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225.
62. Martinelli E., Troiani T., Morgillo F., et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010, 16:4990-5001.
63. Schiller J.H., Flaherty K.T., Redlinger M., et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol 2006, 24:18s. (Abstract 7194).
64. Adjei A.A. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 2007, 5:18S. (Abstract 7547).
65. Blumenschein G.R., Gatzemeier U., Fosella F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small cell lung cancer. J Clin Oncol 2009, 27:4274-4280.
66. Schiller J., Lee J., Hanna N., et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008, 26:427S. (Abstract 8014).
67. Okamoto I., Miyazaki M., Morinaga R., et al. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 2010, 28:844-853.
68. Schiller J.H., Flaherty K.T., Redlinger M., et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol 2006, 24:412S. (Abstract 7194).
69. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
70. Gatzemeier U., Eisen T., Santoro A., et al. Sorafenib (S) + gemcitabine/cisplatin (GC) versus GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010, 21:8S. (Abstract LBA16).
71. Gatzeimer U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
72. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in non-small-cell lung cancer: A phase III trial- INTACT 2. J Clin Oncol 2004, 22:785-794.
73. Haushild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
74. Cho B., Kim S., Heo DS A., et al. multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:15s.
75. Gridelli C., Morgillo F., Favaretto A., et al. Gemcitabine or erlotinib in combination with sorafenib in elderly patients with advanced non small cell lung cancer (GEST): A randomized phase II study. Ann Oncol 2010, 21:8S. (Abstract 422P).
76. Hurwitz H., Dowlati A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009, 15:4220-4227.
77. Altorki N., Lane M.E., Bauer T., et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small cell lung cancer. J Clin Oncol 2010, 28:3131-3137.
78. Gendreau S.B., Ventura R., Keast P., et al. Inhibition of the T790 gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007, 13:3713-3723.
79. Sikic BI, Adjei AA, Halsey J, et al. A phase I study of XL647, an EGFR, Her2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM). Poster presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, November 7-10, 2006.
80. Wakelee H.A., Fehling J.M., Molina J.R., et al. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM). J Clin Oncol 2008, 26:15S. (Abstract 3528).
81. Rizvi NA, Kris M, Miller V, et al. A phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. Poster presented at the International Association for the Study of Lung Cancer (IASLC) 12th World Conference, Seoul, South Korea, September 2-6, 2007.
82. Miller V.A., Wakelee A., Lara P.N., et al. Activity, tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKI: preliminary results of a phase II trial. J Clin Oncol 2008, 26:20s. (Abstract 8028).
83. Bahleda R., Felip E., Herbst R.S., et al. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, early clinical evaluation in patients with advanced solid tumor, non-small cell lung cancer. J Clin Oncol 2008, 26:20s. (Abstract 2564).
84. Balsara B.R., Pei J., Mitsuuchi Y., et al. Frequent activation of AKT in non-small-cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
85. Yamamoto H., Shigemura H., Nomura M., et al. PIK3CA mutations and copy number gains in human lung cancer. Cancer Res 2008, 6913-6921.
86. Tang J.M., He Q.Y., Guo R.X., et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confer poor prognosis. Lung cancer 2006, 51:181-191.
87. Wislez M., Spencer M.L., Izzo J.G., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2006, 65:3226-3235.
88. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ±mice. Proc Natl Acad Sci USA 2001, 98:10320-20325.
89. Aoki M., Blazek E., Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001, 98:136-141.
90. Boffa D.J., Luan F., Thomas D., et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2001, 10:293-300.
91. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
92. Soria J.-C., Lee H.-Y., Lee J.I., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Cancer Res 2002, 8:1178-1184.
93. Lee S.H., Kim H.S., Park W.S., et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002, 110:587-592.
94. Gupta A.K., Soto D.E., Feldman M.D., et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004, 182:151-162.
95. Ihle N.T., Lemos J.R., Wipf P., et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009, 69:143-150.
96. Bianco R., Gelardi T., Damiano V., et al. Mechanisms of resistance to EGFR inhibitors. Targ Oncol 2007, 2:31-37.
97. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
98. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of Akt and and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65:7052-7058.
99. Wislez M., Spencer M.L., Izzo J.G., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2006, 65:3226-3235.
100. Sun SY F.U.H., Khuri F.R. Targeting mTOR signaling for lung cancer therapy. J Thorac Oncol 2006, 1:109-111.
101. Pacey S., Rea D., Steven N., et al. Results of a phase I clinical trial investigating a combination of the oral mTOR inhibitor everolimus (E, RAD001), gemcitabine (GEM) in patients (pts) with advanced cancer. J Clin Oncol 2004, 22:14S. (Abstract 3120).
102. She Q.B., Solit D., Basso A., et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res 2003, 9:4340-4346.
103. Milton D.T., Riely G.J., Azzoli C.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110:599-605.
104. Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial. J Clin Oncol 2007;25:18s (Abstract 7575).
105. Papadimitrakopoulou V, Blumenschein GR, Leighl NB, et al. A phase 1/2 study investigating the combination of RAD001(R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) prevously treated with chemotherapy (C): Phase 1 results. J Clin Oncol 2008;22:20s (Abstract 8051).
106. Leighl N.B., Soria J., Bennouna J., et al. Phase II study of everolimus plus erlotinib in previouly treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:15s. (Abstract 7524).
107. Cappuzzo F., Marchetti A., Skokan M., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009, 27:1667-1674.
108. Bean J., Brennan C., Shih J.Y., et al. MET amplifications occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
109. Laux I., Goldman J., Just R., et al. I Phase dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197, erlotinib. J Clin Oncol 2009, 27:15s. (Abstract 3549).
110. Schiller J.H., Akerley W.L., Brugger W., et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 2010, 28:18s. (Abstract LBA 7502).
111. Sequist L.V., Akerley W.L., Brugger W., et al. Final results from ARQ 197-209: A global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer patients (NSCLC). Ann Oncol 2010, 21:8S. (Abstract 363O).
112. Spigel D., Ervin T., Ramlau R., et al. Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMab, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Ann Oncol 2010, 21:8S. (Abstract LBA15).
113. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
114. Baserga R., Hongo A., Rubini M., et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997, 1332:F105-F126.
115. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999, 91:151-156.
116. Chang Y.S., Wang L., Liu D., et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3669-3675.
117. Chakravartu A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
118. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
119. Van der Veeken J., Oliveira S., Schiffelers R.M., et al. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748-760.
120. Morgillo F., Kim W.Y., Kim E.S., et al. Implications of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13:2795-2803.
121. Cappuzo F., Toschi L., Tallini G., et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006, 17:1120-1127.
122. Ludovini V., Bellezza G., Pistola L., et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009, 20:842-849.
123. Cohen B.D., Baker D.A., Soderstrom C. Etal. Comination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 2005, 11:2063-2073.
124. Han J.Y., Choi B.G., Choi J.Y., et al. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small-cell lung cancer. Lung cancer 2006, 54:227-234.
125. Jassem C., Langer C.J., Karp D.D., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel, carboplatin versus paclitaxel, carboplatin in patients with non-small-cell lung cancer (NSCLC). J Clin Oncol 2010, 28:15S. (Abstract 7500).
126. Kazi A., Lawrence H., Guida W.C., et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009, 8:3074-3075.
127. Scagliotti G. Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 2006, 58:177-189.
128. Davies Am., Lara P.N., Mack P.C., Gandara D.R. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007, 13:s4647-s4651.
129. Denlinger C.E., Rundall B.K., Keller M.D., Jones D.R. Proteasome inhibition sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004, 78:1207-1214.
130. Ling Y.H., Liebes L., Ng B., et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002, 1:841-849.
131. Ling Y.H., Liebes L., Jiang J.D., et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003, 9:1145-1154.
132. Yang Y., Ikezoe T., Saito T., Kobayashi M., Koeffler H.P., Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004, 95:176-180.
133. Zhu H., Zhan L., Dong F., et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005, 24:4993-4999.
134. Mortenson M.M., Schlieman M.G., Virudachalam S., Bold R.J. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004, 54:343-353.
135. Gumerlock P.H., Kawaguchi T., Moisan L.P., et al. Mechanims of enhanced cytotoxicity from docetaxel PS-341 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2002, 21:304a.
136. Fanucchi M.P., Fossella F.V., Belt R., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5025-5033.
137. Li T., Ho L., Piperdi B., Elrafei T., et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung cancer 2010, 68:89-93.
138. Lara P.N., Koczywas M., Quinn D.I., et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 2006, 1:126-134.
139. Ryan D.P., Appleman L.J., Lynch T., et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006, 107:2482-2489.
140. Scagliotti G.V., Germonpré P., Bosquée L., et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung cancer 2010, 68:420-426.
141. Davies A.M., Ruel C., Lara P.N., et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 2008, 3:68-74.
142. Davies A.M., Chansky K., Lara P.N., et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009, 4:87-92.
143. Voortmant J., Smit E.F., Honeywell R., et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007, 13:3642-3651.
144. Subramanian J., Pillot G., Narra V., Govindan R. Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC) A case report. Lung Cancer 2006, 51:257-259.
145. Kris M.G., Giaccone G., Davies A., et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference of bronchioloalveolar carcinoma. J Thorac Oncol 2006, 1:S32-S36.
146. Wheatly-Price P., Shepherd F.A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008, 20:162-175.
147. Schenkein D.P. Preclinical data with bortezomib in lung cancer. Clin Lung Cancer 2005, 7:S49-S55.
148. Piperdi B., Ling Y.H., Perez-Soler R. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. J Thorac Oncol 2007, 2:715-721.
149. Lynch T.J., Fenton D., Hirsc V., et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009, 4:1002-1009.
150. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8:2505-2511.
151. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
152. Johnstone R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
153. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell 2003, 4:13-18.
154. Deroanne C.F., Bonjean K., Servotte S., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endotheliar growth factor signaling. Oncogene 2002, 21:427-436.
155. Maltepe E., Krampitz G.W., Okazaki K.M., et al. Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development 2005, 132:3393-3403.
156. Chen X., Singh T.R., Shankar S., Srivata R.K. In vivo regulation of apoptosis and angiogenesis by histone deacetylase inhibitors and TRAIL in human prostate cancer. Proc Am Assoc Cancer Res 2003, 44:4305.
157. Sun Y., Chin Y.E., Weiger E., et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009, 182:5899-5903.
158. Cuneo K.C., Fu A., Osusky K., Huamani J., Hallahan D.E., Geng L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 2007, 18:793-800.
159. Komatsu N., Kawata N., Takeuchi S., et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006, 15:187-191.
160. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous t-cell lymphoma (CTCL). Blood 2007, 109:31-39.
161. Kelly W.K., ÓConnor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamin acid, in patients with advanced cancer. J Clin Oncol 2005, 3923-3931.
162. Owonikoko T.K., Ramalingam S.S., Kanrewicz B., et al. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010, 126:743-755.
163. Kanzaki M., Kakinuma H., Kumazawa T., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol Rep 2007, 17:761-767.
164. Traynor A.M., Dubey S., Eickhoff J.C., et al. Vorinostat in patients with relapsed non-small-cell lung cancer: A Wisconsin Oncology Network phase II study. J Thorac Oncol 2009, 5:522-526.
165. Ramalingam S.S., Parise R.A., Ramananthan R.K., et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007, 13:3605-3610.
166. Ramalingam S.S., Maitland M.L., Frankel P., et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:56-62.
167. Reid T., Valone F., Lipera W., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (pivanex AN-9) in advanced non-small cell lung cancer. Lung cancer 2004, 45:381-386.
168. Reid T., Weeks A., Vakil M., et al. Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer. J Clin Oncol 2004, 22:685s. (Abstract 7279).
169. Wozniak A., ÓShaughnessy J., Fiorica J., Grove W. Phase II trial of CI-994 in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999, 18:487a. (Abstract 1878).
170. Von Pawel J., Shepherd F., Gatzeimer U., et al. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) versus placebo (PBO) plus Gem in second-line nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21:310a. (Abstract 1239).
171. Von Pawel J, Koschel G, Crino L, et al. Randomized phase II study of the oral histone deacetylase inhibitor CI-994 plus carboplatin (C) and paclitaxel (T) versus placebo (PBO) plus C/T in the first-line treatment of advanced nonsmall cell lung cancer (NSCLC). Prom Am Soc Clin Oncol 2003;22: (Abstract 2518).
172. Prakash S., Foster B.J., Meyer M., et al. Chronic oral administration of CI-994: a phase I study. Invest New Drugs 2001, 19:1-11.
173. Gridelli C., Rossi A., Maione P., et al. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008, 68:29-36.
174. Neal J.W., Sequist L.V. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010, 11:36-44.
175. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524.
176. Reguart A, Cardona AF, Isla D, et al. Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression. J Clin Oncol 2009;27:27s (Abstract e19057).
177. Konduri K, Spira AI, Jotte RM, et al. Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC. J Clin Oncol 2009;27:27s (Abstract e14545).
178. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.
179. Rodriguez-Gonzalez A., Lin T., Ikada A.K., et al. Role of aggresome pathway in cancer: Targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008, 68:2557-2560.
180. Kawaguchi Y., Kovacs J.J., McLaurin A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
181. Hideshima T., Bradner J.E., Wong J., et al. Small-molecule inhibition of proteasome and aggresome function induced synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005, 102:8567-8572.
182. Maiso P., Carvajal-Vergara X., Ocio E.M., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789.
183. Nawrocki S.T., Carew J.S., Pino M.S., et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006, 66:3773-3781.
184. Ninan J.A., Bailey H., Kolesar J., et al. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 2009, 27:15s. (Abstract 2531).
185. Boyault C., Zhang Y., Fritah S., et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of proteins aggregates. Genes Dev 2007, 21:2172-2181.
186. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:751-772.
187. Workman P., Burrows F., Neckers L., et al. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216.
188. Xu W., Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a mutifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007, 1625-1629.
189. Bishop S.C., Burlison J.A., Blagss B.S. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 2007, 7:369-388.
190. Shimamura T., Lowell A.M., Engelman J.A., et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005, 65:6401-6409.
191. Boyault C., Sadoul K., Pabion M., Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007, 26:5468-5476.
192. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
193. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524.
194. Nawrochi S.T., Carew J.S., Pino M.S., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005, 65:11658-11666.
195. Ramanathan R.K., Egorin M.J., Eiseman J.L., et al. Phase I pharmacodynamic study of 17-(allylamino)-17-demethoxy-geldanamycin in adult patients with refractory advanced cancer. Clin Cancer Res 2007, 13:1783-1788.
196. Solit D.B., Ivy S.P., Kopil C., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 15:1775-1782.
197. Ge J., Normant E., Porter J.R., et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-allylamino-17-demethoxygeldanamycin as potent water-soluble inhibitors of Hsp90. J Med Chem 2006, 49:4606-4615.
198. Sydor J.R., Normant E., Pien C.S., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006, 103:17408-17413.
199. Sequist LV, Janne PA, Sweeney J, et al. Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA.
200. Sequist L.V., Gettinger S., Senzer N.N., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
201. Brough P.A., Aherne W., Barril X., et al. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008, 51:196-218.
202. Eccles S.A., Massey A., Raynaud F.I., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor against xenografts tumor growth, angiogenesis and metastasis. Cancer Res 2008, 68:2850-2860.
203. Brough P.A., Barril X., Borgognoni J., et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno 2, 3-d pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009, 52:4794-4809.